Bharat Parenterals Ltd vs Haleos Labs Limited Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 10, 2026

Key Highlights

The Latest Trading Price of Bharat Parenterals Ltd is ₹ 1212 as of 08 May 15:30 . The P/E Ratio of Bharat Parenterals Ltd changed from 9.4 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Haleos Labs Limited changed from 11 on March 2021 to 16.2 on March 2025 . This represents a CAGR of 8.05% over 5 years The Market Cap of Bharat Parenterals Ltd changed from ₹ 192 crore on March 2021 to ₹ 680.55 crore on March 2025 . This represents a CAGR of 28.80% over 5 yearsThe Market Cap of Haleos Labs Limited changed from ₹ 149.61 crore on March 2021 to ₹ 326.64 crore on March 2025 . This represents a CAGR of 16.90% over 5 years The revenue of Bharat Parenterals Ltd for the Dec '25 is ₹ 66.52 crore as compare to the Sep '25 revenue of ₹ 68.15 crore. This represent the decline of -2.39% The revenue of Haleos Labs Limited for the Dec '25 is ₹ 94.97 crore as compare to the Sep '25 revenue of ₹ 81.79 crore. This represent the growth of 16.11% The ebitda of Bharat Parenterals Ltd for the Dec '25 is ₹ 3.07 crore as compare to the Sep '25 ebitda of ₹ 4.35 crore. This represent the decline of -29.43% The ebitda of Haleos Labs Limited for the Dec '25 is ₹ 14.23 crore as compare to the Sep '25 ebitda of ₹ 13.99 crore. This represent the growth of 1.72% The net profit of Bharat Parenterals Ltd changed from ₹ -8.84 crore to ₹ -9.67 crore over 7 quarters. This represents a CAGR of 5.26% The net profit of Haleos Labs Limited changed from ₹ 7.1 crore to ₹ 6.65 crore over 7 quarters. This represents a CAGR of -3.67% The Dividend Payout of Bharat Parenterals Ltd changed from 1.78 % on March 2023 to 2.6 % on March 2025 . This represents a CAGR of 13.46% over 3 yearsThe Dividend Payout of Haleos Labs Limited changed from 3.44 % on March 2021 to 2.12 % on March 2025 . This represents a CAGR of -9.23% over 5 years .

About Bharat Parenterals Ltd

Bharat Parenterals Limited was incorporated in September, 1992 in Gujarat and promoted by Ramesh Desai and Bharat Desai.
The Company is engaged in the business of manufacturing drugs, pharmaceutical formulations and ayurvedic products at its plant in Baroda.
It has set-up a fully integrated and modern plant as per WHO standards at Haripura near Baroda for manufacturing pharmaceutical formulations, life saving drugs, parenterals and antibiotics. In 2016, Varenyam Healthcare Private Limited was incorporated as wholly owned subsidiary company on 09 July, 2016.
Innoxel Lifesciences was incorporated as wholly owned subsidiary company effective 16th October, 2020.
Varenyam Biolifesciences got incorporated as wholly owned subsidiary company effective from 28th June, 2022.

About Haleos Labs Limited

SMS Lifesciences India Limited was incorporated originally as 'Potluri Real Estate Private Limited' on May 31, 2006.
The Company's name was changed to 'Potluri Packaging Industries Private Limited' on 6 November, 2013 and again changed to 'SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector.
The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016. The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates.
The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments.

FAQs for the comparison of Bharat Parenterals Ltd and Haleos Labs Limited

Which company has a larger market capitalization, Bharat Parenterals Ltd or Haleos Labs Limited?

Market cap of Bharat Parenterals Ltd is 835 Cr while Market cap of Haleos Labs Limited is 488 Cr

What are the key factors driving the stock performance of Bharat Parenterals Ltd and Haleos Labs Limited?

The stock performance of Bharat Parenterals Ltd and Haleos Labs Limited is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Parenterals Ltd and Haleos Labs Limited?

As of May 10, 2026, the Bharat Parenterals Ltd stock price is INR ₹1212.65. On the other hand, Haleos Labs Limited stock price is INR ₹1616.7.

How do dividend payouts of Bharat Parenterals Ltd and Haleos Labs Limited compare?

To compare the dividend payouts of Bharat Parenterals Ltd and Haleos Labs Limited, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.